Ibrahim Elsharkawi1, David Gozal2, Eric A Macklin3, Lauren Voelz4, Gil Weintraub5, Brian G Skotko6. 1. Down Syndrome Program, Division of Genetics, Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA. 2. Department of Pediatrics, University of Chicago, Chicago, IL, USA. 3. Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 4. Down Syndrome Program, Division of Developmental Medicine, Department of Medicine, Boston Children's Hospital, Boston, MA, USA. 5. Beth Israel Deaconess Medical Center, Boston, MA, USA. 6. Down Syndrome Program, Division of Genetics, Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA. Electronic address: bskotko@mgh.harvard.edu.
Abstract
STUDY OBJECTIVES: The study aimed to compare urinary biomarkers in patients with Down syndrome (DS) with and without obstructive sleep apnea (OSA) to those of age- and sex-matched neurotypically developing healthy controls (HC). We further investigated whether we could predict OSA in patients with DS using these biomarkers. METHODS: Urine samples were collected from 58 patients with DS the night before or the morning after their scheduled overnight polysomnogram or both, of whom 47 could be age- and sex-matched to a sample of 43 HC. Concentrations of 12 neurotransmitters were determined by enzyme-linked immunosorbent assay. Log-transformed creatinine-corrected assay levels were normalized. Normalized z-scores were compared between patients with DS vs. HC, between patients with DS with vs. without OSA, and to derive composite models to predict OSA. RESULTS: Most night-sampled urinary biomarkers were elevated among patients with DS relative to matched HC. No urinary biomarker levels differed between patients with DS with vs. without OSA. A combination of four urinary biomarkers predicted AHI > 1 with a positive predictive value of 90% and a negative predictive value of 68%. CONCLUSIONS: Having DS, even in the absence of concurrent OSA, is associated with a different urinary biomarker profile when compared to that of HC. Therefore, while urinary biomarkers may be predictive of OSA in the general pediatric population, a different approach is needed in interpreting urinary biomarker assays in patients with DS. Certain biomarkers also seem promising to be predictive of OSA in patients with DS. No clinical trial was indicated in the undertaking of this work.
STUDY OBJECTIVES: The study aimed to compare urinary biomarkers in patients with Down syndrome (DS) with and without obstructive sleep apnea (OSA) to those of age- and sex-matched neurotypically developing healthy controls (HC). We further investigated whether we could predict OSA in patients with DS using these biomarkers. METHODS: Urine samples were collected from 58 patients with DS the night before or the morning after their scheduled overnight polysomnogram or both, of whom 47 could be age- and sex-matched to a sample of 43 HC. Concentrations of 12 neurotransmitters were determined by enzyme-linked immunosorbent assay. Log-transformed creatinine-corrected assay levels were normalized. Normalized z-scores were compared between patients with DS vs. HC, between patients with DS with vs. without OSA, and to derive composite models to predict OSA. RESULTS: Most night-sampled urinary biomarkers were elevated among patients with DS relative to matched HC. No urinary biomarker levels differed between patients with DS with vs. without OSA. A combination of four urinary biomarkers predicted AHI > 1 with a positive predictive value of 90% and a negative predictive value of 68%. CONCLUSIONS: Having DS, even in the absence of concurrent OSA, is associated with a different urinary biomarker profile when compared to that of HC. Therefore, while urinary biomarkers may be predictive of OSA in the general pediatric population, a different approach is needed in interpreting urinary biomarker assays in patients with DS. Certain biomarkers also seem promising to be predictive of OSA in patients with DS. No clinical trial was indicated in the undertaking of this work.
Authors: Eliot S Katz; Mary G Greene; Kathryn A Carson; Patricia Galster; Gerald M Loughlin; John Carroll; Carole L Marcus Journal: J Pediatr Date: 2002-05 Impact factor: 4.406
Authors: Peter Nieminen; Tuija Löppönen; Uolevi Tolonen; Peter Lanning; Mikael Knip; Heikki Löppönen Journal: Pediatrics Date: 2002-04 Impact factor: 7.124
Authors: Maria S Trois; George T Capone; Janita A Lutz; Maria C Melendres; Alan R Schwartz; Nancy A Collop; Carole L Marcus Journal: J Clin Sleep Med Date: 2009-08-15 Impact factor: 4.062
Authors: A W Coppus; D Fekkes; W M A Verhoeven; S Tuinier; J I M Egger; C M van Duijn Journal: J Neural Transm (Vienna) Date: 2007-03-31 Impact factor: 3.575
Authors: Carole L Marcus; Lee Jay Brooks; Kari A Draper; David Gozal; Ann Carol Halbower; Jacqueline Jones; Michael S Schechter; Sally Davidson Ward; Stephen Howard Sheldon; Richard N Shiffman; Christopher Lehmann; Karen Spruyt Journal: Pediatrics Date: 2012-08-27 Impact factor: 7.124
Authors: Brian G Skotko; Eric A Macklin; Marco Muselli; Lauren Voelz; Mary Ellen McDonough; Emily Davidson; Veerasathpurush Allareddy; Yasas S N Jayaratne; Richard Bruun; Nicholas Ching; Gil Weintraub; David Gozal; Dennis Rosen Journal: Am J Med Genet A Date: 2017-01-26 Impact factor: 2.578
Authors: Sandra Giménez; Laura Videla; Sergio Romero; Bessy Benejam; Susana Clos; Susana Fernández; Maribel Martínez; Maria Carmona-Iragui; Rosa M Antonijoan; Mercedes Mayos; Ana Fortuna; Patricia Peñacoba; Vicente Plaza; Ricardo S Osorio; Ram A Sharma; Ignasi Bardés; Anne-Sophie Rebillat; Alberto Lleó; Rafael Blesa; Sebastian Videla; Juan Fortea Journal: J Clin Sleep Med Date: 2018-10-15 Impact factor: 4.062
Authors: Sarah Grantham-Hill; Hazel J Evans; Catherine Tuffrey; Emma Sanders; Heather E Elphick; Paul Gringras; Ruth N Kingshott; Jane Martin; Janine Reynolds; Anna Joyce; Catherine M Hill; Karen Spruyt Journal: Front Psychiatry Date: 2020-04-28 Impact factor: 4.157